Open AccessErelzi<sup>®</sup> – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)
Author(s) -
В. И. Мазуров,
А. М. Лила,
T. Korotaeva
Publication year - 2021
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2021-4-129-131
Subject(s) - biosimilar , etanercept , medicine , psoriasis , psoriatic arthritis , adverse effect , clinical trial , antirheumatic drugs , clinical practice , intensive care medicine , physical therapy , antirheumatic agents , disease , rheumatoid arthritis , dermatology
of biosimilars of biological disease-modifying antirheumatic drugs (bDMARs) into clinical practice has significantly expanded the availability of bDMARD therapy for a wide range of patients with chronic immuno-inflammatory diseases.In 2020, the first biosimilar etanercept Erelzi ® , was registered in the Russian Federation. On May 22, 2021, an interdisciplinary Expert panel meeting was held on the use of Erelzi ® for the treatment of rheumatic diseases and psoriasis. The leading Russian rheumatologists and dermatologists participated in this meeting. In the resolution of the Expert panel, it was stated that according data from randomized clinical trials and real clinical practice and due to low immunogenic potential of Erelzi, it can be used in initial therapy and in switching from other bDMARDs therapy in patients, who develop adverse reactions or face loss of their therapy effectiveness.